Trial Profile

Efficacy of alemtuzumab in pateints with relapsing-remitting multiple sclerosis: one year real world study

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 30 Oct 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alemtuzumab (Primary)
Indications Multiple sclerosis
Focus Therapeutic Use
Acronyms PROMiS

Most Recent Events

30 Oct 2018 New trial record
12 Oct 2018 Interim results (n=171) assessing patient reported outcomes PRO over 8 months after initiation of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis, presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com